The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders
_Limited_256_384.jpg)
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
Glucon-D maintained its leadership position with a 59% MAT market share
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
